A UK-based KOL discusses epidemiology and patient segmentation of Acute Lymphoblastic Leukemia (ALL) in the UK, including differences by age group, disease subtype, and newly diagnosed versus relapsed/refractory populations. It then explores real-world treatment pathways across the ALL-disease course, discussing frontline and relapsed management strategies, the roles of chemotherapy, asparaginases, TKIs, monoclonal antibodies, stem cell transplantation, and CAR-T therapies. Finally, the discussion addresses emerging and pipeline therapies, regulatory and access considerations, unmet needs in specific patient subgroups, and anticipated future directions in ALL treatment.

This interview was conducted on August 12, 2025.

If you are a Datamonitor Healthcare client, you may access the interview from our KOL Insight channel.

If you are a KOL Insight subscriber, you may also access the interview from our KOL Insight portal.

Biomedtracker’s KOL Insight transcripts are available through subscription only. For more information on obtaining a KOL Insight subscription, please email Biomedtracker or call Biomedtracker Client Services at (888) 670-8900. 

For our disclosures, please read the Biomedtracker Research Standards.